Ab­b­Vie hands Voy­ager a mega-bil­lions gene ther­a­py deal, with $310M in near-term cash

Gene ther­a­py com­pa­ny Voy­ager Ther­a­peu­tics has kicked off 2019 in style. Af­ter forg­ing an up to $1.8 bil­lion pact with Neu­ro­crine last month, the Parkin­son’s drug de­vel­op­er ex­pand­ed its part­ner­ship with Ab­b­Vie on Fri­day, days fol­low­ing the an­niver­sary of their orig­i­nal pact.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER